Arman Yucel, Kirna Kerem, Ugurlukisi Bilal, Kutlu Orkide, Dikker Okan, Cil Eylem Ozgun, Akarsu Murat, Ozcan Mustafa, Yuruyen Gulden, Demir Pinar, Altun Ozgur, Ozsenel Ekmel Burak, Erdem Mustafa Genco, Sandikci Riza, Tukek Tufan
Internal Medicine, Okmeydani Research and Education Hospital, Istanbul, Turkey.
Department of Medical Biochemistry, Istanbul Okmeydani Training and Research Hospital, Istanbul, Turkey.
Exp Clin Endocrinol Diabetes. 2017 Apr;125(4):262-266. doi: 10.1055/s-0042-118862. Epub 2017 Jan 10.
Omentin-1, an adipocytokine that increases the insulin sensitivity, has been determined to be reduced in patients with insulin resistance, impaired glucose tolerance, and Type-2 diabetes mellitus. In this study, we have investigated the alterations in Omentin-1 levels with the blood glucose regulation in diabetic patients having poor glycemic control. By this way, we aimed to determine the role of Omentin-1 as a marker in follow-up and monitoring progression of diabetes. Totally 58 patients with type 2 diabetes mellitus, older than 18 years of age who were having poor glycemic control (HbA1c≥9) were included in this study. In the first visit, all clinical and biochemical parameters of patients were recorded. After baseline evaluation, the patients were advised life style changes, and their medical treatment was determined individually according to the recommendations of the American Diabetes Association guidelines. At the end of the third month patients were re-evaluated. Serum Omentin-1 levels were measured with ELISA. In patients using only oral antidiabetic agents, after exchanging the treatment with insulin, on 3 month of treatment, there was a significant decrease in serum C-peptide and Omentin-1 levels compared with the initial results (p=0.034, p=0.048, respectively). On the other hand, in patients using insulin treatment from the beginning of the study, there was not any significant alterations in serum C-peptide or Omentin-1 levels compared with the initial results (p>0.05). Serum Omentin-1 levels may change with insulin and metformin treatments in Type-2 diabetic patients. In patients with poor glycemic control, Omentin-1 levels do not change with the regulation of blood glucose levels. A decrease in Omentin-1 and C-peptide levels has been determined after the initiation of insulin therapy. This suggests that, Omentin-1 levels are closely associated with the endogenous insulin reserve and may be used in follow-up of patients.
网膜素-1是一种可提高胰岛素敏感性的脂肪细胞因子，已确定在胰岛素抵抗、糖耐量受损和2型糖尿病患者中其水平会降低。在本研究中，我们调查了血糖控制不佳的糖尿病患者中网膜素-1水平随血糖调节的变化情况。通过这种方式，我们旨在确定网膜素-1作为糖尿病随访和监测病情进展标志物的作用。本研究共纳入58例年龄大于18岁、血糖控制不佳（糖化血红蛋白≥9）的2型糖尿病患者。在首次就诊时，记录患者的所有临床和生化参数。基线评估后，建议患者改变生活方式，并根据美国糖尿病协会指南的建议为其个体化确定治疗方案。在第三个月末对患者进行重新评估。采用酶联免疫吸附测定法检测血清网膜素-1水平。仅使用口服降糖药的患者，在改用胰岛素治疗3个月后，血清C肽和网膜素-1水平与初始结果相比显著降低（分别为p = 0.034和p = 0.048）。另一方面，从研究开始就使用胰岛素治疗的患者，血清C肽或网膜素-1水平与初始结果相比无显著变化（p>0.05）。2型糖尿病患者的血清网膜素-1水平可能会随胰岛素和二甲双胍治疗而改变。在血糖控制不佳的患者中，网膜素-1水平不会随血糖水平的调节而变化。开始胰岛素治疗后，已确定网膜素-1和C肽水平会降低。这表明，网膜素-1水平与内源性胰岛素储备密切相关，可用于患者的随访。
